MSK hematologist-oncologist Dr. Lia Palomba led a clinical trial that resulted in FDA approval of lisocabtagene maraleucel (Breyanzi®), a CAR T cell therapy, for marginal zone lymphoma. Marginal zone ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback